^
Association details:
| Biomarker: | STAT3 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug Class: | STAT3 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2432 - Somatic mutations in the STAT3 activation pathway are associated with improved survival in gynecologic malignancies and provide a molecular rationale for therapeutic targeting
Published date:
03/14/2021
Excerpt:
Pharmacologic and genetic (siRNA) inhibition of the STAT3 activation pathway killed PARP inhibitor-resistant ovarian cancer cells in-vitro. Clinically, somatic mutations in the STAT3 activation pathway were associated with improved OS in both ovarian and uterine cancer
